Boston-(Business wire-Gelesis (NYSE: GLS), a manufacturer of plenity for weight management, has received weight loss and additional metabolism in mice that have undergone microbial transplantation from another group of mice treated with one of the company’s own hydrogels. We have released new preclinical data showing efficacy. The benefit of these metabolisms is that while both groups of mice that are donors of microbial transplants and mice of recipients are on a high-fat, high-carbohydrate diet that usually causes rapid weight gain, obesity, and diabetes. Occurred in. The findings were presented today at the American Diabetes Association’s annual meeting.
Gelesis’s super-absorbent hydrogels are inspired by the composition (cellulose structure that retains water) and mechanical properties (elasticity or hardness) of the raw vegetables ingested. They are taken by capsules filled with water before meals and create much larger amounts of small non-aggregating hydrogel pieces that act locally in the digestive system without adding calories.One of the hydrogels is marketed as Plenity® To support weight management. Others that utilize the same platform technology are in clinical and preclinical studies.
In April, Gelesis presented preclinical data at the World of Microbiome conference, adding superabsorbent hydrogel (Gel-B, candidate) to a high-fat “Western-style” diet and adding diet-related intestines. Suggested to prevent adverse changes in the bacterial community. Induced weight gain. This study showed a significant effect on the composition of the intestinal flora, Akkermansia muciniphila, Bacterial species associated with intestinal health and weight loss. Importantly, the addable fiber (denatured cellulose) used as a positive control did not support the growth of these species. This same type of modified cellulose is used to create Gelesis’s unique hydrogel. The difference in bacterial growth between linear fibers and 3D hydrogels suggests that the effect of hydrogels on the microbial phase is primarily mechanical (ie, elastic response or hardness). In previous studies, administration of one of these hydrogels in addition to a high-fat diet slowed weight gain, reversed intestinal atrophy, improved metabolic parameters, and restored the intestinal barrier.
This new study reduces the harmful effects of diet by transferring microbiota from gel B-treated mice to the intestines of mice fed a high-fat, high-carbohydrate, high-cholesterol (HFHCC) diet for 10 weeks. The purpose is to investigate whether it can be done.
“This study provides strong evidence that regulation of the gut microbiota by Gelesis’s hyperabsorbable hydrogels is likely to play a mechanical role in the weight loss and metabolic effects of this intervention.” Said Dr. Maria Rescigno, Group Leader of the Mucosal Immunology and Microbial System Unit. She is one of the principal investigators at the University of Humanitas in Milan. She found that “microbiota in obese animals on a high-fat diet can be modified with Gel-B treatment to become” lean microbiota. ” This Gel-B-induced lean microbial flora was then found to be contagious because it caused weight loss in obese mice not treated with Gel-B. ”
This study used gut microbiota migration (IMT) to investigate the functional role of gut microbiota and explained the metabolic effects associated with Gel-B treatment. Metabolic disease was induced in two cohorts of mice (“donor” and “recipient”) by consuming a high-fat, high-cholesterol, high-carbohydrate diet for 10 weeks. Donors continued HFHCC or received HFHCC and Gel-B for an additional 6 weeks. Fecal samples were treated from donors every other day for 2-6 weeks of treatment. Recipients received a transfer of gut flora from a Gel-B treated or untreated donor. Recipients receiving IMT from untreated donors continue to gain weight, and recipients receiving IMT from gel-B treated donors lose weight despite continued consumption of HFHCC. Did. Treating the recipient with the intestinal flora of the donor treated with Gel B also resulted in improved glycemic control.
An interview with research author Dr. Rescigno is available at https://youtu.be/AsmUo7lnQbs.
About Gelesis
Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis”) is a consumer-centric biotherapy company and manufacturer of Plenity.®, This is naturally inspired and the FDA has allowed it to assist in weight management. Our first kind of non-systemic superabsorbent hydrogel is made from completely naturally derived building blocks. Inspired by the composition and mechanical properties of raw vegetables ingested by capsules, they act locally in the digestive system, so people feel satisfied with the small parts.Our portfolio includes Plenity® Potential treatment under development for patients with type 2 diabetes, non-alcoholic steatohepatitis (NAFLD) / non-alcoholic steatohepatitis (NASH), and functional constipation. For more information, please visit gelesis.com or contact us on Twitter @ Gelesis Inc.
Abundance® When used in combination with diet and exercise, it has been shown to help weight management in overweight and obese adults. Body mass index (BMI) is 25-40 kg / m².
Important safety information about Plenity
-
Do not take Plenity if you are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide.
-
To avoid affecting the absorption of the drug:
-
For all medications that need to be taken with a meal, take them after starting a meal.
-
For all medications that need to be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your doctor.
-
-
The overall incidence of side effects from Plenity was similar to that of placebo. The most common side effects were diarrhea, bloating, rare bowel movements, and flatulence.
-
Contact your doctor immediately if you encounter any problems. If you have a severe allergic reaction, severe abdominal pain, or severe diarrhea, discontinue use of Plenity until you can consult your doctor.
Rx only. For safe and proper use of Plenity or more information, consult your healthcare professional, read the patient’s instruction manual, or call 1-844-PLENITY.
Description of future prospects
Certain statements, estimates, goals, and forecasts in this press release may constitute “forward-looking statements” within the meaning of federal securities law. “Expect”, “Believe”, “Continue”, “Done”, “Estimate”, “Expect”, “Intention”, “May”, “May”, “Plan”, Expressions such as “possible,” “possible,” “predict,” “plan,” “should,” “strive,” and “do” describe future prospects. However, the absence of these words does not mean that the description is not forward-looking. Forward-looking statements are forecasts, forecasts, and other statements about future events based on current expectations and assumptions, and are subject to risks and uncertainties as a result. Forward-looking statements include, but are not limited to, forward-looking statements, hopes, beliefs, intentions, or strategies of the Company or its management. ”) And its expected profits, Gelesis’s performance after the business combination, the competitive environment in which Gelesis does business, Gelesis’s expected future business and financial performance and market opportunities, and Gelesis’ expectations, hopes, beliefs and intentions. , Or a statement about the strategy future. In addition, statements that refer to forecasts, forecasts, or other features of future events or situations are forward-looking statements, including underlying assumptions. Forward-looking statements are provided only as of the date they were created. Readers should be careful not to place excessive reliance on forward-looking statements. Gelesis does not undertake or intend to revise any of these forward-looking statements as a result of new information, future events, etc. Gelesis does not warrant that the expectations set forth in this press release will be met. Due to various risks, uncertainties (some of which are beyond our control) or other factors, actual future results, performance or events may differ materially from those described in this document. I have. Factors that may affect future results and performance include, but are not limited to: (I) Market size, demand, growth potential of Plenity® and other Gelesis product candidates, and Gelesis’ ability to serve those markets. (Ii) Degree of market acceptance and adoption of Gelesis products. (Iii) Gelesis’ ability to develop innovative products and compete with other companies engaged in the weight loss industry. (Iv) Gelesis’ ability to fund and successfully complete the commercial launch of Plenity® and its growth plans. This includes new potential indications and clinical data from current and future studies of the liver and other diseases. (V) Failure to realize the expected benefits of the business combination, including the consequences of delays or difficulties in the integration of Capstar and Gelesis businesses. (Vi) Gelesis’s ability to issue equity or equity-linked securities in the future and to raise debt financing. (Vii) The result of legal proceedings filed against Capstar, Gelesis, or others in connection with the business combination. (Viii) Gelesis’ ability to stay listed on the New York Stock Exchange. (Ix) The risk that a business combination will disrupt Gelesis’ current plans and operations as a result of Gelesis being a listed issuer. (X) Regulatory channels for Gelesis products and responses from regulators, including the FDA and similar regulators outside the United States. (Xi) The ability of Gelesis to grow, manage growth in a profitable manner, maintain relationships with customers and suppliers, and retain Gelesis managers and key employees. (Xii) Costs related to business combinations, including costs related to the listed issuer Gelesis. (Xiii) Changes in applicable law or regulation. (Xiv) Gelesis may be adversely affected by other economic, business, regulatory and / or competitive factors. (Xv) Cost and profitability estimates by Gelesis. (Xvi) ongoing regulatory requirements, (xvii) potential competing products or technologies, (xviii) volatility in the general telemedicine market, or inadequate patient demand. (Xix) The ability of Gelesis to protect its intellectual property and meet regulatory requirements. (Xx) Impact of the COVID19 pandemic on Gelesis’ business. (Xxi) Limited operation history of Gelesis. (Xxii) The potential impact of inflation on our operating and commodity costs. (Xxiii) Other important factors described in the “Risk Factors” section of Gelesis’s latest annual report on Form 10-K and other filings submitted by Gelesis to the Securities and Exchange Commission. These filings address other significant risks and uncertainties in which actual results and events may differ materially from those contained in the forward-looking statements.
